{"organizations": [], "uuid": "5431e1e9b8e1fd6a4364c8d2a5695997936d7b7f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/27/globe-newswire-coherus-biosciences-to-report-fourth-quarter-and-full-year-2017-financial-results-on-march-8th.html", "country": "US", "domain_rank": 767, "title": "Coherus BioSciences to Report Fourth Quarter and Full Year 2017 Financial Results on March 8th", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-27T17:00:00.000+02:00", "replies_count": 0, "uuid": "5431e1e9b8e1fd6a4364c8d2a5695997936d7b7f"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/27/globe-newswire-coherus-biosciences-to-report-fourth-quarter-and-full-year-2017-financial-results-on-march-8th.html", "ord_in_thread": 0, "title": "Coherus BioSciences to Report Fourth Quarter and Full Year 2017 Financial Results on March 8th", "locations": [], "entities": {"persons": [], "locations": [{"name": "redwood city", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}], "organizations": [{"name": "coherus biosciences, inc.", "sentiment": "neutral"}, {"name": "coherus biosciences, inc", "sentiment": "none"}, {"name": "coherus biosciences", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "REDWOOD CITY, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its fourth quarter and full year 2017 financial results will be released after market close on Thursday, March 8, 2018. At 4:30 p.m. Eastern Time, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.\nAfter releasing fourth quarter and full year 2017 financial results, we will post them on the Coherus BioSciences website at http://investors.coherus.com .\nConference Call Information\nWhen: Thursday, March 8, 2018 at 4:30 p.m. ET\nDial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International)\nConference ID: 7098068\nWebcast: http://investors.coherus.com\nPlease join the conference call at least 10 minutes early to register. The webcast will be archived on the Coherus website.\nAbout Coherus BioSciences, Inc.\nCoherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com .\nCONTACT:\nPatrick O’Brien\nSenior Vice President, Investor Relations\nCoherus BioSciences, Inc.\npobrien@coherus.com\n+1 (650) 649-3527\nSource:Coherus BioSciences, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=KPD3G6f1B37MmwPVG8kAFhWayA4nd-kxShwTtPOo21koOcQOTdXtJVeHBixGZbgLzxKnvTTxPfdUIghnW8CMyw==", "https://www.globenewswire.com/Tracker?data=l7L4snnTs7G30sG51pPIvTyE3sdJX6pafjEKhaczEvK3aNpwqxyMG7SqLc--sYfHiEMK82tBaNwFsyjO_Thn2lb82P59F4j4v6hT839DSkIuUpnU78YaRA_Z1Y2U2a4KxcPlr928qKr2px39ZjULXl8Hv956XauIwIQ8XtFcwHEdbwApyjx5qby2-vlcWh0HtuSzfN_LNGqWkTRdrDclmQ==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/37b5e3e4-4132-49a4-a83a-94920550245f", "https://www.globenewswire.com/Tracker?data=sCf2hb6j6NlRZhIw82B7VcLeIHiPzVfU7Atj98SiP3ZfqepWEPYWPiPvOY7_Dcny2SUoRcs3Rc5dJjffBK-e05pZdrE5oZBAR0_rjGgqRqg=", "https://www.globenewswire.com/Tracker?data=b661B-9DqrunIm3hzwRwECnHJHiLooMi7fJpFPj7HAEVNt6oh284amsAWhmzNDb0y1F8Y_UcaczlUtcMaNfazjdgBxvR1M4uT3iHrHJoi80=", "https://www.globenewswire.com/Tracker?data=b661B-9DqrunIm3hzwRwECnHJHiLooMi7fJpFPj7HAEQfZ4S3GFD8lgGleorkOX9O56Fa8jb1ZUvW0-9tnqguMha2V4r-dI_BldbdSTDAgk="], "published": "2018-02-27T17:00:00.000+02:00", "crawled": "2018-02-27T16:37:44.086+02:00", "highlightTitle": ""}